iRadimed Analyst Price Targets - Benzinga

iRadimed Corp

IRMDNASDAQ

Trade with Public

Trade with Public

$89.65

0.180.2%

最終更新: Oct 13, 4:00 PM

$89.47

N/A

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

iRadimed Analyst Price Targets - Benzinga

iRadimed Analyst Price Targets

Wall Street analyst price targets and consensus rating for iRadimed (IRMD).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

2Buy

1Hold

Consensus RatingBuy# Analysts3Avg. Consensus PT$94Upside to Avg. PT+4.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	Needham	David Saxon	Initiate	Hold	—
Apr 2, 2026	Freedom Broker	Ilya Zubkov	Initiate	Buy	$116
Feb 14, 2025	Roth MKM	Jason Wittes	PT Raise	Buy	$60→$72
Aug 2, 2024	Roth MKM	Jason Wittes	PT Cut	Buy	$65→$60
Apr 22, 2024	Roth MKM	Jason Wittes	Reinstates	Buy	$65

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Initiates Coverage On iRadimed with Hold Rating

Needham analyst David Saxon initiates coverage on iRadimed (NASDAQ:IRMD) with a Hold rating.

Benzinga Newsdesk

PRO
Roth MKM Reiterates Buy on iRadimed, Raises Price Target to $72

Roth MKM analyst Jason Wittes reiterates iRadimed (NASDAQ:IRMD) with a Buy and raises the price target from $60 to $72.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on iRadimed, Lowers Price Target to $60

Roth MKM analyst Jason Wittes maintains iRadimed (NASDAQ:IRMD) with a Buy and lowers the price target from $65 to $60.

Benzinga Newsdesk

PRO
Roth MKM Reinstates Buy on iRadimed, Announces $65 Price Target

Roth MKM analyst Jason Wittes reinstates iRadimed (NASDAQ:IRMD) with a Buy and announces $65 price target.

Benzinga Newsdesk

PRO
UPDATE: Roth On iRadimed Price Target Raise: Firm Highlights Strong Monitor Sales Offsetting Pump Sales With Co. On Track For All-Time Revenue Highs; Expects Next-Gen Pump To Be Approved Late 2021 To Early 2022 Which Could Further Surge Revenues

Benzinga Newsdesk

PRO
Roth Capital Maintains Buy on iRadimed, Raises Price Target to $36

Roth Capital analyst Scott Henry maintains iRadimed (NASDAQ:IRMD) with a Buy and raises the price target from $32 to $36.

Benzinga Newsdesk